Pharmaceutical company Galderma has received approval from the US Food and Drug Administration (FDA) for the correction of temple hollowing using Restylane Contour.
The company states that the approval is based on clinical data from Galderma demonstrating that Restylane Contour – part of its portfolio of hyaluronic acid injectables – delivers natural-looking results lasting up to 18 months, alongside high levels of patient satisfaction.
In the study of 225 participants, 70% reported feeling they looked younger, less tired and more refreshed 18 months after treatment, and 85% felt their temples still looked natural at 18 months.
Board certified dermatologist and dermatologic surgeon Mark Nestor commented, “We’re at a time where aesthetic preferences and needs are evolving faster than ever. People are increasingly seeking subtle, harmonising enhancements that keep them looking refreshed and youthful, and temple volume has an important role to play in this. While age‑related changes are still the primary driver, we’re also seeing phenomena like medication‑driven weight loss accelerating hollowing in this area. Having Restylane Contour now approved for the temples in the US gives us a highly adaptable tool that aligns perfectly with today’s demand for natural-looking results that support total facial balance.”
Bill Andriopoulos, head of global medical affairs at Galderma, commented,“This approval for Restylane Contour with an innovative injection technique is yet another demonstration of our ongoing commitment to ensuring our trusted products deliver what healthcare professionals need to meet diverse aesthetic goals. For example, as rates of medication-driven weight loss expand, we’re seeing greater need for treatments that can address associated facial volume changes. Restylane Contour for temples aligns with this rising demand, providing a natural and authentic way to restore